| Outcome Measures: |
Primary: Number of participants with adverse events, To assess the safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Follow-up visit/Early discontinuation visit (EDV) (7-14 Days Post-last PK Sample)|Number of participants with abnormal findings in electrocardiography (ECG), To assess abnormal resting digital 12-lead electrocardiograms as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)|Number of participants with abnormal pulse rate, To assess abnormal pulse rate as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)|Number of participants with abnormal hematology, To assess white blood cell count (WBC), red blood cell count (RBC), neutrophils absolute count, lymphocytes absolute count, monocytes absolute count, eosinophils absolute count, basophils absolute count, platelets, and reticulocytes absolute count as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)|Number of participants with abnormal blood pressure (systolic and diastolic), To assess abnormal blood pressure (systolic and diastolic) as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)]|Number of participants with abnormal physical examination, To assess safety and tolerability by assessment of the general appearance, respiratory, cardiovascular, abdomen, skin, head, and neck (including ears, eyes, nose, and throat), lymph nodes, thyroid, musculoskeletal and neurological systems., From screening up to Follow-up visit/EDV (7-14 Days Post-last PK sample)]|Number of participants with abnormal electrolytes, To assess serum level of sodium, potassium, calcium (total), and phosphate as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Follow-up visit/EDV (7-14 Days Post-last PK smaple)]|Number of participants with abnormal hemoglobin (Hb), To assess Hb as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)|Number of participants with abnormal hematocrit, To assess hematocrit as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)|Number of participants with abnormal Mean corpuscular volume (MCV), To assess MCV as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)|Number of participants with abnormal mean corpuscular hemoglobin (MCH), To assess MCH as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)|Number of participants with abnormal mean corpuscular hemoglobin concentration (MCHC), To assess MCHC as a variable of safety and tolerability of verinurad and allopurinol in healthy Asian and Chinese participants., From screening up to Followup visit/EDV (7-14 Days Postlast PK Sample)|Number of participants with abnormal clinical chemistry, To assess the safety and tolerability profile of verinurad and allopurinol treatment in terms of the number of participants with abnormal clinical chemistry values. The laboratory variables to be measured are: bilirubin, creatinine, albumin, alkaline phosphatase (ALP), alanine aminotransferase (ALT), aspartate aminotransferase (AST), cystatin C, gamma glutamyl transpeptidase, urea and uric acid., From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample)|Number of participants with abnormal urinalysis., To assess the safety and tolerability profile of verinurad and allopurinol treatment in terms of the number of participants with abnormal urinalysis values. The laboratory variables to be measured are: protein, glucose, blood, uric acid, pH, sodium, creatinine, and cystatin C., From screening up to Follow-up visit/EDV (7-14 Days Post-last PK Sample) | Secondary: Area under plasma concentration-time curve from zero to infinity (AUC), AUC(0-t), AUC(0-24), and AUCτ, To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants., On Day 1, Days 3 to 6, Day 7 (cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2).|Observed concentration and percentage change from baseline in serum uric acid, To evaluate serum uric acid of verinurad and allopurinol treatment in terms of the number of participants with observed concentration and percentage change from baseline in serum uric acid., On Day -1: -24, -21, -18, and -12 hours prior to dosing on Day 1. On Days 1, 7 and 9 (Pre-dose, 3, 6, 12, and 24 hours post-dose).|Observed concentration and percentage change from baseline in urine uric acid, To evaluate urine uric acid of verinurad and allopurinol treatment in terms of the number of participants with observed concentration and percentage change from baseline in urine uric acid., On Day -1: baseline collection of urine: -24 to -22 h, -22 h to -20 h, -18 h to -16 h, -16 h to - 12 h and -12 h to 0 h prior to dosing on Day 1, on Days 1, 7 and 9 (0-2 h, 2-4 h, 4-6 h, 6-8 h, 8-12 h, and 12-24 h post-dose).|Maximum observed plasma concentration (Cmax) and Minimum observed plasma concentration (Cmin), To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants., On Day 1, Days 3 to 6, Day 7(cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2)|Time to reach maximum observed plasma concentration (tmax) and Time of last measurable concentration (tlast), To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants., On Day 1, Days 3 to 6, Day 7 (cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2).|Apparent total body clearance of drug from plasma after extravascular administration across the dosing interval (CL/F), To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants., On Day 1, Days 3 to 6, Day 7(cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2)|Half-life associated with terminal slope (λz) of a semi-logarithmic concentration-time curve (t½λz), To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants., On Day 1, Days 3 to 6, Day 7(cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2)|Apparent volume of distribution based on the terminal phase (Vz/F) and Apparent volume of distribution during the terminal phase after extravascular administration (Vss/F), To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants., On Day 1, Days 3 to 6, Day 7 (cohort 1). On Day 1, Day 2, Days 3 to 8, and Day 9 (Cohort 2)|Mean residence time (MRT), To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants., On Day 1|Accumulation ratio for Cmax and AUCτ, To evaluate the pharmacokinetics of verinurad, allopurinol and oxypurinol in healthy Asian and Chinese participants., On Day 7 (Cohort 1) or Day 9 (Cohort 2)
|
